Key terms

About LEXX

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest LEXX news

Apr 16 3:07pm ET Lexaria Advances with New GLP-1 Drug Study by TipRanks Apr 16 9:30am ET Lexaria Bioscience receives ethics review board approval for GLP-1 study by TipRanks Apr 02 12:37pm ET Lexaria Secures New Patents, Bolsters Pharma Tech by TipRanks Mar 21 1:07pm ET Lexaria Bioscience Showcases Drug Delivery Breakthrough by TipRanks Mar 14 12:37pm ET Lexaria Bioscience Welcomes New CFO by TipRanks Mar 12 5:11pm ET Lexaria Bioscience files to sell 1.61M shares of common stock for holders by TipRanks Mar 07 1:37pm ET Lexaria Bioscience Advances Oral Diabetes Treatment by TipRanks Mar 07 9:11am ET Lexaria Bioscience hires CRO for GLP-1 human pilot study by TipRanks Mar 05 12:37pm ET Lexaria Tests New Diabetes and Weight Loss Formulations by TipRanks Mar 05 11:33am ET Lexaria Bioscience price target raised to $12 from $3 at Maxim by TipRanks Mar 04 12:37pm ET Lexaria Advances Drug Delivery with Promising Study by TipRanks Mar 04 9:20am ET Lexaria Bioscience says DehydraTECH-CBD study resulted in weight loss in rodents by TipRanks Mar 01 8:23am ET Lexaria Bioscience announces FDA clearance of Phase 1b hypertension trial by TipRanks Feb 15 8:07am ET Lexaria Bioscience prices $3.6M registered direct offering at $2.31 per share by TipRanks Jan 30 8:50am ET Lexaria Bioscience submits IND application to FDA for DehydraTECH-CBD trial by TipRanks Jan 24 8:54am ET Lexaria Bioscience says ‘never been more confident’ in IP portfolio by TipRanks Jan 22 3:01pm ET Analysts Offer Insights on Healthcare Companies: Lexaria Bioscience (LEXX), Evolus (EOLS) and Inspire Medical Systems (INSP) by TipRanks
Mar 21 9:20am ET Lexaria to Present at The LD Micro Invitational XIV by Newsfile

LEXX Financials

1-year income & revenue

Key terms

LEXX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

LEXX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

A bubble tea store operated by Sichuan Baicha Baidao in Shanghai, China, on April 23, 2024.
Raul Ariano/Bloomberg/Getty Images
Is the tea bubble bursting? ChaPanda shares plunge in Hong Kong IPO
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Can markets make a comeback? That depends on tech earnings
People walk past the New York Stock Exchange Thursday, March. 21, 2024.
Yuki Iwamura/AP
Investors are fearful. They shouldn’t be
People walk past the New York Stock Exchange (NYSE) on March 28, 2024 in New York City.
NDZ/STAR MAX/IPx/AP
What stalled this year’s seemingly infallible stock market rally